STOCK TITAN

Enveric Biosciences, Inc. - ENVB STOCK NEWS

Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.

Enveric Biosciences, Inc. (ENVB) is a pioneering biotechnology company committed to the development of innovative neuroplastogenic small-molecule therapeutics aimed at treating mental health conditions such as depression, anxiety, and addiction disorders. Headquartered in the United States, Enveric is at the forefront of mental health research, with a focus on non-hallucinogenic solutions.

The company's flagship program, EB-003, represents a novel approach to tackling challenging mental health disorders. Unlike traditional treatments, EB-003 promotes neuroplasticity without causing hallucinations, providing a safer and potentially more effective option for patients.

Another key project in Enveric's pipeline is EB-002, previously known as EB-373. This next-generation synthetic prodrug of psilocin is being developed to offer new hope in the treatment of psychiatric disorders. With an emphasis on rigorous scientific research and clinical trials, Enveric strives to deliver breakthrough therapies that can significantly improve patients' quality of life.

Enveric's strategic vision includes forming partnerships and collaborations to enhance its research capabilities and accelerate the development of its therapeutic programs. Highlighting its commitment to innovation, the company is also investing in cutting-edge technologies such as artificial intelligence (AI) to further its research and development efforts.

Financially, Enveric Biosciences has been transparent about its funding efforts, ensuring that it maintains a robust financial foundation to support its research initiatives. With a strong commitment to ethical practices and patient-centric solutions, Enveric is emerging as a key player in the biotech sector, focused on addressing some of the most pressing mental health challenges of our time.

Rhea-AI Summary
Enveric Biosciences (NASDAQ: ENVB) announces the sale of a cancer-related patent portfolio to focus on developing neuroplastogenic small-molecule therapeutics for mental health disorders. The company will invest in lead candidates EB-003 and EB-002, targeting depression, anxiety, and addiction disorders. Enveric plans to continue research and development in this area while providing foundational patent protection for the undisclosed purchasers of the divested portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.29%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences (ENVB) to initiate preclinical development of EB-003 in 2024 in preparation for IND submission
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences (ENVB) announces agreements with holders of existing warrants to exercise at a reduced price, resulting in approximately $1.8 million in gross proceeds. The new warrants will allow for the purchase of up to 2,244,000 shares of common stock at an exercise price of $1.37 per share over a term of five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
none
Rhea-AI Summary
Enveric Biosciences (ENVB) to initiate preclinical development of EB-003 in 2024 for IND submission
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.72%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences (ENVB) Announces Positive Progress in GLP Safety and Toxicology Program for EB-373
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
-
Rhea-AI Summary
Enveric Biosciences (ENVB) to participate in Biotech Showcase 2024, presenting business and clinical development strategy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences
Rhea-AI Summary
Enveric Biosciences (ENVB) has identified three novel neuroplastic compounds from its EVM301 Series with the potential to offer a first-in-class approach to address difficult-to-treat disorders by promoting neuroplasticity without inducing hallucinations. The company plans to select one of the compounds for preclinical development early in 2024 in anticipation of Investigational New Drug (IND) application for a first-in-human clinical trial. Enveric’s research team successfully narrowed the EVM301 Series to three candidates with preclinical data indicating 5HT2A receptor binding, induction of neuroplasticity, and positive stress recovery outcomes in animal models showing no indication of hallucinations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences (ENVB) has received a Notice of Allowance from the USPTO for a patent application pertaining to its EVM301 Series of molecules, aiming to develop treatments for mental health disorders. The company is focused on developing compounds that engage neurotransmitter receptors to promote neuroplasticity, with the goal of generating therapeutic benefit without inducing hallucinations. Enveric has filed multiple composition of matter patent applications with the USPTO, and to date, has received nine Notices of Allowance for patent applications claiming compounds in the EVM201 and EVM301 Series.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.44%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences (ENVB) announces the development of lead therapeutic candidate EB-373, a novel psilocin prodrug, to be published in the Journal of Medicinal Chemistry. The compound offers potential benefits for the treatment of anxiety disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
none
Rhea-AI Summary
Enveric Biosciences (ENVB) presented two posters at the Canadian Chemical Engineering Conference (CSChE 2023) showcasing the biocatalytic production of MDMA and other phenylpropylamine derivatives, as well as a synthetic biology platform for the production of novel indolethylamine derivatives as drug candidates to treat anxiety and depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none

FAQ

What is the current stock price of Enveric Biosciences (ENVB)?

The current stock price of Enveric Biosciences (ENVB) is $0.3333 as of November 22, 2024.

What is the market cap of Enveric Biosciences (ENVB)?

The market cap of Enveric Biosciences (ENVB) is approximately 3.4M.

What does Enveric Biosciences specialize in?

Enveric Biosciences specializes in developing neuroplastogenic small-molecule therapeutics for treating depression, anxiety, and addiction disorders.

What is EB-003?

EB-003 is Enveric's lead program designed to promote neuroplasticity in treating mental health disorders without inducing hallucinations.

What is EB-002?

EB-002, formerly known as EB-373, is a next-generation synthetic prodrug of psilocin being developed for the treatment of psychiatric disorders.

Where is Enveric Biosciences headquartered?

Enveric Biosciences is headquartered in the United States.

How does Enveric Biosciences fund its research?

Enveric Biosciences maintains a robust financial foundation through transparent funding efforts to support its research initiatives.

Is Enveric involved in any partnerships or collaborations?

Yes, Enveric forms strategic partnerships and collaborations to enhance its research capabilities and accelerate its therapeutic programs.

How does Enveric ensure its treatments do not cause hallucinations?

Enveric focuses on non-hallucinogenic solutions, as evidenced by its lead program, EB-003, which promotes neuroplasticity without causing hallucinations.

What technologies is Enveric investing in?

Enveric is investing in cutting-edge technologies such as artificial intelligence (AI) to advance its research and development efforts.

What are the core values of Enveric Biosciences?

Enveric Biosciences is committed to ethical practices, patient-centric solutions, and innovative research to address mental health challenges.

Why is Enveric considered a key player in the biotech sector?

Enveric is emerging as a key player due to its pioneering approaches to mental health treatments and significant investments in innovative research.

Enveric Biosciences, Inc.

Nasdaq:ENVB

ENVB Rankings

ENVB Stock Data

3.38M
9.22M
6.93%
7.06%
3.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NAPLES